StockNews.com Lowers Omnicell (NASDAQ:OMCL) to Hold

StockNews.com cut shares of Omnicell (NASDAQ:OMCL) from a buy rating to a hold rating in a report issued on Thursday morning.

Several other research analysts also recently weighed in on the company. Barclays upgraded Omnicell from an underweight rating to an equal weight rating and upped their price target for the stock from $26.00 to $39.00 in a research note on Friday, August 2nd. JPMorgan Chase & Co. raised their target price on shares of Omnicell from $26.00 to $37.00 and gave the company a neutral rating in a research note on Friday, August 23rd. Bank of America boosted their price target on shares of Omnicell from $34.00 to $44.00 and gave the stock a buy rating in a research note on Friday, August 2nd. Wells Fargo & Company raised their price objective on Omnicell from $26.00 to $30.00 and gave the company an equal weight rating in a research report on Friday, August 2nd. Finally, Benchmark reiterated a buy rating and issued a $38.00 target price on shares of Omnicell in a research report on Monday, July 15th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of Hold and a consensus price target of $37.83.

Omnicell Stock Performance

Shares of OMCL stock opened at $44.62 on Thursday. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47. The company has a 50 day moving average price of $39.21 and a 200-day moving average price of $32.31. Omnicell has a 52 week low of $25.12 and a 52 week high of $53.37. The firm has a market capitalization of $2.05 billion, a PE ratio of -97.00, a P/E/G ratio of 49.47 and a beta of 0.83.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. The business had revenue of $276.80 million during the quarter, compared to the consensus estimate of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The business’s quarterly revenue was down 7.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.29 EPS. As a group, equities research analysts expect that Omnicell will post 0.64 earnings per share for the current year.

Institutional Investors Weigh In On Omnicell

Several hedge funds have recently bought and sold shares of the stock. Arizona State Retirement System increased its holdings in Omnicell by 2.9% in the second quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock valued at $348,000 after buying an additional 357 shares in the last quarter. Texas Permanent School Fund Corp raised its holdings in Omnicell by 1.2% in the 1st quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company’s stock worth $1,158,000 after purchasing an additional 479 shares during the period. Diversified Trust Co boosted its position in Omnicell by 3.3% during the second quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock worth $416,000 after purchasing an additional 494 shares in the last quarter. Louisiana State Employees Retirement System grew its holdings in Omnicell by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock valued at $625,000 after purchasing an additional 600 shares during the period. Finally, ProShare Advisors LLC increased its position in shares of Omnicell by 7.4% in the first quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock valued at $265,000 after buying an additional 626 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.